Published in Eur J Immunol on July 01, 2007
Involvement of IFN-γ and perforin, but not Fas/FasL interactions in regulatory T cell-mediated suppression of experimental autoimmune encephalomyelitis. J Neuroimmunol (2010) 1.07
BAFF upregulates CD28/B7 and CD40/CD154 expression and promotes mouse T and B cell interaction in vitro via BAFF receptor. Acta Pharmacol Sin (2016) 0.75
Multiple sclerosis--the plaque and its pathogenesis. N Engl J Med (2006) 6.60
Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol (2006) 3.38
T-bet is essential for encephalitogenicity of both Th1 and Th17 cells. J Exp Med (2009) 2.96
T-bet regulates the fate of Th1 and Th17 lymphocytes in autoimmunity. J Immunol (2007) 2.86
Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol (2006) 2.62
Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol (2005) 2.55
Silencing T-bet defines a critical role in the differentiation of autoreactive T lymphocytes. Immunity (2004) 2.24
Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol (2005) 2.02
Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis. JAMA Neurol (2013) 2.00
Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Arch Neurol (2008) 1.88
Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J Immunol (2002) 1.83
Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med (2011) 1.81
Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease. J Immunol (2004) 1.62
High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay. Blood (2004) 1.62
Th1 versus Th17: are T cell cytokines relevant in multiple sclerosis? Biochim Biophys Acta (2010) 1.50
Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis. J Immunol (2006) 1.48
Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis. J Clin Invest (2002) 1.36
miR-29ab1 deficiency identifies a negative feedback loop controlling Th1 bias that is dysregulated in multiple sclerosis. J Immunol (2012) 1.35
Agonists for the peroxisome proliferator-activated receptor-alpha and the retinoid X receptor inhibit inflammatory responses of microglia. J Neurosci Res (2005) 1.32
Micro-RNA dysregulation in multiple sclerosis favours pro-inflammatory T-cell-mediated autoimmunity. Brain (2011) 1.27
IL-1 receptor-associated kinase 1 regulates susceptibility to organ-specific autoimmunity. J Immunol (2003) 1.21
Peroxisome proliferator-activated receptor-alpha agonist fenofibrate regulates IL-12 family cytokine expression in the CNS: relevance to multiple sclerosis. J Neurochem (2007) 1.19
Ligands for the peroxisome proliferator-activated receptor-gamma and the retinoid X receptor exert additive anti-inflammatory effects on experimental autoimmune encephalomyelitis. J Neuroimmunol (2004) 1.19
Receptor revision and atypical mutational characteristics in clonally expanded B cells from the cerebrospinal fluid of recently diagnosed multiple sclerosis patients. J Neuroimmunol (2005) 1.14
Monoclonal antibody therapies and neurologic disorders. Arch Neurol (2008) 1.14
Peroxisome proliferator-activated receptor-alpha and retinoid X receptor agonists inhibit inflammatory responses of astrocytes. J Neuroimmunol (2006) 1.13
Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor κB (NF-κB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1) signaling. J Biol Chem (2012) 1.13
Memory B cells from a subset of treatment-naïve relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein. Eur J Immunol (2010) 1.13
Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Arch Neurol (2010) 1.11
Peroxisome proliferator-activated receptor agonist regulation of glial activation: relevance to CNS inflammatory disorders. Neurochem Int (2006) 1.11
Lymph node-derived donor encephalitogenic CD4+ T cells in C57BL/6 mice adoptive transfer experimental autoimmune encephalomyelitis highly express GM-CSF and T-bet. J Neuroinflammation (2011) 1.11
Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions. Arch Neurol (2007) 1.09
TGF-β signaling via Smad4 drives IL-10 production in effector Th1 cells and reduces T-cell trafficking in EAE. Eur J Immunol (2011) 1.06
Reactivation of human herpesvirus-6 in natalizumab treated multiple sclerosis patients. PLoS One (2008) 1.05
Transcriptional modulation of the immune response by peroxisome proliferator-activated receptor-{alpha} agonists in autoimmune disease. J Immunol (2009) 1.03
Antigen specificity of clonally expanded and receptor edited cerebrospinal fluid B cells from patients with relapsing remitting MS. J Neuroimmunol (2007) 1.03
Multiple toll-like receptor agonists act as potent adjuvants in the induction of autoimmunity. J Neuroimmunol (2005) 1.02
Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies. Biol Blood Marrow Transplant (2010) 1.02
Silencing Nogo-A promotes functional recovery in demyelinating disease. Ann Neurol (2010) 1.02
Impact of myelin-specific antigen presenting B cells on T cell activation in multiple sclerosis. Clin Immunol (2008) 0.98
Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis. PLoS One (2011) 0.97
Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosis. J Neuroimmunol (2009) 0.96
Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis? Expert Rev Neurother (2009) 0.95
miRNA profiling for biomarker discovery in multiple sclerosis: from microarray to deep sequencing. J Neuroimmunol (2011) 0.95
Retinoic acid promotes the development of Th2-like human myelin basic protein-reactive T cells. Cell Immunol (2002) 0.95
Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study. Arch Neurol (2009) 0.93
Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations. Arch Neurol (2005) 0.92
A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis. Ther Adv Neurol Disord (2010) 0.91
PEG minocycline-liposomes ameliorate CNS autoimmune disease. PLoS One (2009) 0.90
Porcine endothelial cells, unlike human endothelial cells, can be killed by human CTL via Fas ligand and cannot be protected by Bcl-2. J Immunol (2002) 0.89
TGF-beta enhances effector Th1 cell activation but promotes self-regulation via IL-10. J Immunol (2010) 0.89
PPAR Alpha Regulation of the Immune Response and Autoimmune Encephalomyelitis. PPAR Res (2008) 0.89
Mycophenolate mofetil in multiple sclerosis. Clin Neuropharmacol (2004) 0.88
Targeting T cell costimulation in autoimmune disease. Expert Opin Ther Targets (2002) 0.87
PPAR-gamma: Therapeutic Potential for Multiple Sclerosis. PPAR Res (2008) 0.86
Pharmacological prion protein silencing accelerates central nervous system autoimmune disease via T cell receptor signalling. Brain (2010) 0.86
Glatiramer acetate (GA) therapy induces a focused, oligoclonal CD8+ T-cell repertoire in multiple sclerosis. J Neuroimmunol (2006) 0.85
Pharmacological treatment of early multiple sclerosis. Drugs (2008) 0.84
What happens when natalizumab therapy is stopped? Expert Rev Neurother (2011) 0.82
Clonal composition of neuroantigen-specific CD8+ and CD4+ T-cells in multiple sclerosis. J Neuroimmunol (2011) 0.82
The neonatal CNS is not conducive for encephalitogenic Th1 T cells and B cells during experimental autoimmune encephalomyelitis. J Neuroinflammation (2013) 0.82
Phenotypic characterization of autoreactive T cells in multiple sclerosis. J Neuroimmunol (2006) 0.81
CD28-CD57+ T cells predominate in CD8 responses to glatiramer acetate. J Neuroimmunol (2006) 0.81
Regulation of Immune Responses and Autoimmune Encephalomyelitis by PPARs. PPAR Res (2010) 0.80
The potential role of B cell-targeted therapies in multiple sclerosis. Drugs (2010) 0.80
Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab. JAMA Neurol (2013) 0.80
High incidence of post-lumbar puncture headaches in patients with multiple sclerosis treated with natalizumab: role of intrathecal leukocytes. Arch Neurol (2007) 0.80
Comparison of a classical Th1 bacteria versus a Th17 bacteria as adjuvant in the induction of experimental autoimmune encephalomyelitis. J Neuroimmunol (2011) 0.79
Translational research in neurology and neuroscience 2010: multiple sclerosis. Arch Neurol (2010) 0.79
A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS). Ther Adv Neurol Disord (2010) 0.78